Product information and disease descriptionPlace of product in therapyDisease description
Diagnosis
11 evidence topics · 10 sources
Clinical diagnosis with biopsy in doubtful cases
Clinical assessment: body surface area, PASI, PGA, and DLQI
“Psoriasis is assessed by the extent of skin involvement (body surface area (BSA)) and the severity of erythema, induration and scaling. In secondary care, validated scores such as Psoriasis Area Severity Index (PASI) and Physician Global Assessment Scale are routinely used along with patient reported outcome measures such as Dermatology Life Quality Index (DLQI).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Measures of disease activity: PASI, PGA, body surface area, and DLQI
“Although it has its drawbacks, the most established parameter to measure the severity of skin symptoms in patients with psoriasis is the Psoriasis Area and Severity Index (PASI), which was first introduced in 1978 as an outcome measure in a retinoid trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A physician global assessment (PGA) score to evaluate disease severity can be beneficial in daily clinical care in order to rapidly assess the severity of psoriasis. It is important to note that different PGAs exist and that they may differ in the way they are defined and scales that are used. An estimate of the percentage of the affected body surface area (BSA) is also used as a means to measure disease severity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“So far, the Dermatology Life Quality Index (DLQI) has been the most commonly used score for assessing the impact of psoriasis on HRQoL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Body surface area estimated by palm count
Limitations of PASI and other clinical severity measures: systematic review of 53 measures
“The purpose of this study was to identify all clinical measures of psoriasis severity and outcome in use and to evaluate the quality of these measures using clinimetric criteria; we identified 53 separate clinical measures, which were regrouped into 11 measures for quality analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The Psoriasis Area and Severity Index is the most commonly used clinical measure in research, but it has substantial limitations such as low response distribution, no consensus on interpretability, and low responsiveness in mild disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Reliability of PASI, body surface area, and PGA
“In all 3 scales the ICCs were > 0.75, indicating high intra-rater reliability. The highest ICC was for the BSA (0.96) and the lowest one for the PGA (0.87). The CV for the PGA and PASI were 29.3 and 36.9, respectively, indicating moderate inter-rater variability. The CV for the BSA was 57.1, indicating high inter-rater variability.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Five-point Investigator's Global Assessment scale
“The Psoriasis Area and Severity Index (PASI) score is most widely used as a primary endpoint in clinical trials, although it is not routinely used in clinical practice.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 5-point IGA has a more stringent definition for a score of 1 ("almost clear") compared with 6-point IGA/Physician's Global Assessment (PGA) tools used in previous trials of other biologics in moderate-to-severe psoriasis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Dermatology Life Quality Index score bands
“DLQI scores 0-1 = no effect on patient's life (GQ = 0, n = 754); DLQI scores 2-5 = small effect on patient's life (GQ = 1, n = 611); DLQI scores 6-10 = moderate effect on patient's life (GQ = 2, n = 327); DLQI scores 11-20 = very large effect on patient's life (GQ = 3, n = 242); DLQI scores 21-30 = extremely large effect on patient's life (GQ = 4, n = 59)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Severity classification: mild and moderate-to-severe definitions with upgrade criteria
“Currently, the disease definition most commonly used for psoriasis is strongly influenced by the definition used in clinical trials. It was thoroughly discussed and formally agreed upon in a European consensus project in 2011.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Severity classification: topical or systemic candidacy
“This most preferred statement rejects the mild, moderate, and severe categories in favor of a dichotomous definition: Psoriasis patients should be classified as either candidates for topical therapy or candidates for systemic therapy; the latter are patients who meet at least one of the following criteria: (1) body surface area >10%, (2) disease involving special areas, and (3) failure of topical therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote